# A Study of Rituximab (MabThera) in Participants With Chronic Lymphocytic Leukemia (CLL)

> **NCT02533401** · PHASE2 · COMPLETED · sponsor: **Hoffmann-La Roche** · enrollment: 34 (actual)

## Conditions studied

- Lymphocytic Leukemia, Chronic

## Interventions

- **DRUG:** Cyclophosphamide
- **DRUG:** Fludarabine
- **DRUG:** Rituximab

## Key facts

- **NCT ID:** NCT02533401
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-02
- **Primary completion:** 2014-12
- **Final completion:** 2014-12
- **Target enrollment:** 34 (ACTUAL)
- **Last updated:** 2016-05-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02533401

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02533401, "A Study of Rituximab (MabThera) in Participants With Chronic Lymphocytic Leukemia (CLL)". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT02533401. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*